The Work of Trek Pharmaceuticals

1. The Work of Trek
Pharmaceuticals
By: Robert Hindes, MD

2. The Work of Trek Pharmaceuticals
The chief medical officer and cofounder of Trek Therapeutics, Robert Hindes, MD, works
alongside the Trek team to develop affordable treatments for viral infections, including
hepatitis C (HCV). Previously leading clinical virology activities at Bristol-Myers Squibb in
Wallingford, Connecticut, and Pharmasset in Princeton, NJ, Robert Hindes, MD, now
provides oversight for all of Trek’s clinical developments.

3. The Work of Trek Pharmaceuticals
Bringing together talented researchers from various areas of the medical profession, Trek
Therapeutics is a public benefit corporation that has made it its goal to help patients
worldwide gain access to affordable treatments for viral infections.

4. The Work of Trek Pharmaceuticals
The company is currently conducting trials to determine the efficacy of Faldaprevir
combined with other anti-viral drugs for the treatment of HCV.

5. The Work of Trek Pharmaceuticals
In September 2016, Trek made available the results of its Phase 2a study of the drug,
which examined the effectiveness of Faldaprevir when combined with TD-6450 and RBV.
Patients in the study received 120 milligrams (mg) of Faldaprevir, combined with 120 or
60mg of TD-6450, and weight based RBV. In that study, all 16 patients with chronic
genotype 4 HCV treated for 12 weeks experienced a sustained viral response to the
medication 12 weeks after completion of treatment (SVR12). The same drug regimen
was subsequently evaluated in patients with genotype 1b HCV infection, and shown to be
highly effective in HCV genotype 1b as well as genotype 4.

6. The Work of Trek Pharmaceuticals
The genotype 4 study was presented at the 26th Conference of the Asian Pacific
Association for the Study of the Liver ( APASL) on February, 2017, in Shanghai, China.
The results are considered to be extremely encouraging. Further clinical trials are
currently being conducted by Trek with a goal of developing a treatment regimen
affordable for most patients in middle-income countries, and in higher income countries
for certain populations with poor access to treatment.